Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials

[Display omitted]

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JACC. Heart failure 2021-11, Vol.9 (11), p.803-806
Hauptverfasser:	Cheng, Richard K., Maurer, Mathew S.
Format:	Artikel
Sprache:	eng
Schlagworte:	amyloidosis HFpEF mineralocorticoid antagonists transthyretin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	806
container_issue	11
container_start_page	803
container_title	JACC. Heart failure
container_volume	9
creator	Cheng, Richard K. Maurer, Mathew S.
description	[Display omitted]
doi_str_mv	10.1016/j.jchf.2021.07.005
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2572212550</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2213177921003875</els_id><sourcerecordid>2572212550</sourcerecordid><originalsourceid>FETCH-LOGICAL-c333t-b5267a1982980642020b3143f849005f31e1a7a74e886b0b98cd8262fa4205f33</originalsourceid><addsrcrecordid>eNp9UMtqwzAQFKWFhjQ_0JOOvdjVw7Zk6CWEpAkEWkpyFrIspzK25EpOIX9fmZQeu5fdYWeWnQHgEaMUI1w8t2mrPpuUIIJTxFKE8hswIwTTBDPObv9mVt6DRQgtisVzzDmfgcOHVu5kzWichdLWcNcPnVFywgG6Bh5tbeTJuqBruJI-AgWX_aVzpobvkabtGKCxcLsZ1ht48EZ24QHcNbHpxW-fg-NmfVhtk_3b62613CeKUjomVU4KJnHJSclRkcX_UUVxRhueldFEQ7HGkkmWac6LClUlVzUnBWlk5MY1nYOn693Bu6-zDqPoTVC666TV7hwEyVm0TvIcRSq5UpV3IXjdiMGbXvqLwEhMKYpWTCmKKUWBmIgPRNHLVaSjiW-jvQgqGla6Nl6rUdTO_Cf_AXnteMM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2572212550</pqid></control><display><type>article</type><title>Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials</title><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Cheng, Richard K. ; Maurer, Mathew S.</creator><creatorcontrib>Cheng, Richard K. ; Maurer, Mathew S.</creatorcontrib><description>[Display omitted]</description><identifier>ISSN: 2213-1779</identifier><identifier>EISSN: 2213-1787</identifier><identifier>DOI: 10.1016/j.jchf.2021.07.005</identifier><language>eng</language><publisher>Elsevier Inc</publisher><subject>amyloidosis ; HFpEF ; mineralocorticoid antagonists ; transthyretin</subject><ispartof>JACC. Heart failure, 2021-11, Vol.9 (11), p.803-806</ispartof><rights>2021 American College of Cardiology Foundation</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c333t-b5267a1982980642020b3143f849005f31e1a7a74e886b0b98cd8262fa4205f33</citedby><cites>FETCH-LOGICAL-c333t-b5267a1982980642020b3143f849005f31e1a7a74e886b0b98cd8262fa4205f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids></links><search><creatorcontrib>Cheng, Richard K.</creatorcontrib><creatorcontrib>Maurer, Mathew S.</creatorcontrib><title>Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials</title><title>JACC. Heart failure</title><description>[Display omitted]</description><subject>amyloidosis</subject><subject>HFpEF</subject><subject>mineralocorticoid antagonists</subject><subject>transthyretin</subject><issn>2213-1779</issn><issn>2213-1787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9UMtqwzAQFKWFhjQ_0JOOvdjVw7Zk6CWEpAkEWkpyFrIspzK25EpOIX9fmZQeu5fdYWeWnQHgEaMUI1w8t2mrPpuUIIJTxFKE8hswIwTTBDPObv9mVt6DRQgtisVzzDmfgcOHVu5kzWichdLWcNcPnVFywgG6Bh5tbeTJuqBruJI-AgWX_aVzpobvkabtGKCxcLsZ1ht48EZ24QHcNbHpxW-fg-NmfVhtk_3b62613CeKUjomVU4KJnHJSclRkcX_UUVxRhueldFEQ7HGkkmWac6LClUlVzUnBWlk5MY1nYOn693Bu6-zDqPoTVC666TV7hwEyVm0TvIcRSq5UpV3IXjdiMGbXvqLwEhMKYpWTCmKKUWBmIgPRNHLVaSjiW-jvQgqGla6Nl6rUdTO_Cf_AXnteMM</recordid><startdate>202111</startdate><enddate>202111</enddate><creator>Cheng, Richard K.</creator><creator>Maurer, Mathew S.</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202111</creationdate><title>Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials</title><author>Cheng, Richard K. ; Maurer, Mathew S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c333t-b5267a1982980642020b3143f849005f31e1a7a74e886b0b98cd8262fa4205f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>amyloidosis</topic><topic>HFpEF</topic><topic>mineralocorticoid antagonists</topic><topic>transthyretin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheng, Richard K.</creatorcontrib><creatorcontrib>Maurer, Mathew S.</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>JACC. Heart failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheng, Richard K.</au><au>Maurer, Mathew S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials</atitle><jtitle>JACC. Heart failure</jtitle><date>2021-11</date><risdate>2021</risdate><volume>9</volume><issue>11</issue><spage>803</spage><epage>806</epage><pages>803-806</pages><issn>2213-1779</issn><eissn>2213-1787</eissn><abstract>[Display omitted]</abstract><pub>Elsevier Inc</pub><doi>10.1016/j.jchf.2021.07.005</doi><tpages>4</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 2213-1779
ispartof	JACC. Heart failure, 2021-11, Vol.9 (11), p.803-806
issn	2213-1779 2213-1787
language	eng
recordid	cdi_proquest_miscellaneous_2572212550
source	Alma/SFX Local Collection; EZB Electronic Journals Library
subjects	amyloidosis HFpEF mineralocorticoid antagonists transthyretin
title	Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T00%3A08%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recognition%20and%20Implications%20of%20Undiagnosed%20Cardiac%20Amyloid%20Patients%20in%20HFpEF%20Trials&rft.jtitle=JACC.%20Heart%20failure&rft.au=Cheng,%20Richard%20K.&rft.date=2021-11&rft.volume=9&rft.issue=11&rft.spage=803&rft.epage=806&rft.pages=803-806&rft.issn=2213-1779&rft.eissn=2213-1787&rft_id=info:doi/10.1016/j.jchf.2021.07.005&rft_dat=%3Cproquest_cross%3E2572212550%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2572212550&rft_id=info:pmid/&rft_els_id=S2213177921003875&rfr_iscdi=true